Flowonix Medical and Cerebral Therapeutics said today that the 1st patients were implanted with the Prometra II programmable infusion system in a clinical trial evaluating the pump in patients with refractory epilepsy. The Address trial marks the 1st time a programmable, implantable pump has been used to deliver medication, in this case valproate, directly to […]
Neurological
Cerveau Technologies, Wisconsin Alzheimer’s Center ink research deal
Cerveau Technologies said today that it landed a clinical research agreement with the University of Wisconsin-Madison Alzheimer’s Research Center to study an early stage imaging agent with positron emission tomography scans to assess the status and progression of neurofibrillary tangles in the brain. Neurofibrillary tangles composed of tau protein are characteristic of certain neurodegenerative diseases, […]
Study: Localized delivery of chemo improves prognosis of recurrent glioblastoma
Researchers from Amrita University in India demonstrated that localized and sustained delivery of a chemotherapeutic agent in brain tumors can improve the prognosis of recurrent glioblastoma. The team’s work was published in Scientific Reports. Although new drugs have been developed for glioblastoma multiforme, the overall survival rate for patients remains dismally low at 12 months, with […]
FDA asks Titan for more info before clinical trial of ropinirole implant
Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA put a hold on the clinical trial of its ropinirole implant and told the company to submit more information to the federal watchdog. After it completed an initial review of the implant’s Investigational New Drug application, the FDA asked Titan for final release test data on its ropinirole […]
Acorda’s inhaled Parkinson’s drug meets primary endpoint in Phase III trial
Acorda Therapeutics (NSDQ:ACOR) said today that the phase III clinical trial evaluating its inhaled formulation of Parkinson’s drug levodopa met its primary endpoint. The drug was studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The randomized phase III trial enrolled 339 patients to evaluate the efficacy […]
Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy. In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said […]
Early research shows shark antibodies carrying drugs across blood-brain barrier
Danish pharmaceutical company Lundbeck made an undisclosed milestone payment to biotech Ossianix Inc., after experiments showed that shark antibodies effectively shuttled potential drugs across the blood-brain barrier in mice. The 2 companies established a research collaboration in 2014, focusing on technology development and the delivery of antibody-based therapies across the blood-brain barrier. Ossianix said that […]
Study shows Alzheimer’s drug activates stem cells in teeth
Researchers from King’s College London have shown that an Alzheimer’s drug can stimulate the stem cells found in tooth pulp and generate a protective material, dentine, in large cavities. The team’s work was published yesterday in Scientific Reports. If the soft pulp of a tooth becomes infected after a traumatic event, a thin layer of dentine is […]
Neurelis closes Series B for intranasal diazepam spray
Neurelis, Inc. said today that it closed a Series B financing round, led by HBM Healthcare Investments. Other investors included LYZZ Capital, which previously led a Series A funding round for the company. Neurelis will use the funds to complete clinical trials for its intranasal diazepam spray and prepare a new drug application to submit […]
Neurelis wins fast track designation from FDA for intranasal diazepam spray
Neurelis, Inc. said today that it won fast track designation from the FDA for its intranasal diazepam spray. The nasal formulation of diazepam, which is being developed for pediatric and adult epilepsy patients who experience repititive or cluster seizures, is in the final stage of clinical development, according to Neurelis. The company expects to submit […]
